Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Effectiveness of Guselkumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis
ChiCTR2400089608Phase 4Not yet recruiting
- Sponsor
- Shenzhen Nanshan People's Hospital
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of guselkumab in plaque psoriasis, sponsored by Shenzhen Nanshan People's Hospital. Primary endpoint: Psoriasis Area and Severity Index (PASI). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400089608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089608.